Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
Authors not listed
Oraya Therapeutics, Inc. · 2012
Abstract
The purpose of this study is to confirm the clinical and economic benefits of IRay treatment with respect to the number of anti-VEGF injections and frequency of visits during the first year after treatment for patients with wet Age-related Macular Degeneration (AMD).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-09 MST
Cite this
APA
Anonymous. (2012). A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). <em>Oraya Therapeutics, Inc.</em>. https://clinicaltrials.gov/study/NCT01521065
Vancouver
Anonymous. A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD). Oraya Therapeutics, Inc.. 2012.
BibTeX
@misc{anon2012AMulti,
title = {A Multicenter, Open-label Study to Evaluate the Clinical and Economic Benefits of Low Voltage Stereotactic Radiotherapy in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)},
author = {Anonymous},
journal = {Oraya Therapeutics, Inc.},
year = {2012},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
American Journal of Ophthalmology 2007
Citation only
Ranibizumab According to Need: A Treatment for Age-related Macular Degeneration
NeoVista 2008
Open access · US-GOV
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration in Patients That Require Persistent Anti-VEGF Therapy
Ophthalmology 2006
Citation only
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Allergan 2007
Open access · US-GOV
Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)
Nature reviews. Immunology 2013
Preprint · OA
Immunology of age-related macular degeneration
Alkahest, Inc. 2018
Open access · US-GOV